Table 3 Immunological screening at 3 months (n = 46) and 12 months (n = 20).
Exploration | Abnormal exploration at 3 months (n = 46), n (%) | Persistent abnormalities at 12 months (n = 20), n (%) |
|---|---|---|
Full blood count | 3/46 (6.52) | 2/20 (10.00) |
Jolly’s bodies | 0/39 (0.00) | 0/20 (0.00) |
Ig (IgG, A, M) | 10/43 (23.26) | 6/20 (30.00) |
IgG subclasses (IgG1,2,3 and 4) | 3/17 (17.65)** | 1/17 (5.88) |
Post-vaccinal serologies | 15/39 (38.46)*** | 1/19 (5.26) |
Complement | 3/22 (13.64)* | 1/16 (6.25) |
CRP | 8/42 (19.04) | 0/20 (0.00) |
Ferritin | 6/40 (15.00) | 2/20 (10.00) |
Lymphocyte immunophenotyping | 26/45 (57.78) | 8/20 (40.00) |
CD4 + T cells | 8/45 (17.78) | 1/20 (5.00) |
CD8 + T cells | 7/45 (15.56) | 4/20 (20.00) |
B cells | 5/45 (11.11) | 1/20 (5.00) |
NK cells | 15/45 (33.33) | 5/20 (25.00) |
T CD4 sub population | 8/43 (18.60) | 0/20 (0.00) |
T CD8 sub population | 20/40 (50.00) | 6/20 (30.00) |
B sub population | 18/30 (60.00)** | 7/17 (41.18) |
Genetic testing (PID or FHL-panel by NGS) | 3/9 (33.33) | – |
